News

Business Insider1y
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023 - Markets Insider
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City ...
Business Insider1y
Expert Ratings for Verona Pharma - Markets Insider
Verona Pharma (NASDAQ:VRNA) has observed the following analyst ratings within the last quarter: According to 6 analyst offering 12-month price targets in the last 3 months, Verona Pharma has an ...
Nasdaq4y
Verona Pharma Enters into $219M Ensifentrine Collaboration with Nuance Pharma - Nasdaq
Clinical-stage biopharmaceutical company Verona Pharma (VRNA) has granted specialty pharmaceutical company Nuance Pharma the development and commercialization rights for its ensifentrine in the ...
Yahoo Finance2y
Verona Pharma strengthens commercialization leadership team
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on ...